Goodwin Advises Alesta Therapeutics in Acquisition by BioMarin for up to $490 Million
August 18, 2026
August 18, 2026
BOSTON, Massachusetts, Aug. 18 [Category: BizLaw/Legal] -- Goodwin, a law firm, posted the following news release:
* * *
Goodwin Advises Alesta Therapeutics in Acquisition by BioMarin for up to $490 Million
*
The Life Sciences M&A team advised Alesta Therapeutics on their definitive agreement to be acquired by BioMarin, a global rare disease biotechnology company. Under the terms of the agreement, BioMarin will acquire Alesta, and Alesta sh . . .
* * *
Goodwin Advises Alesta Therapeutics in Acquisition by BioMarin for up to $490 Million
*
The Life Sciences M&A team advised Alesta Therapeutics on their definitive agreement to be acquired by BioMarin, a global rare disease biotechnology company. Under the terms of the agreement, BioMarin will acquire Alesta, and Alesta sh . . .